脂質異常症診療Q&A

出版社： 日本医学出版
著者：
発行日： 2011-01-11
分野： 臨床医学：一般  >  栄養/食事/輸血
ISBN： 9784902266481
電子書籍版： 2011-01-11 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,180 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,180 円(税込)

購入する

商品紹介

動脈硬化性疾患予防のための脂質異常症の日常診療における様々な疑問点を139のQ&A形式にて第一線の臨床の専門家が解説。冒頭に座談会「ガイドラインを実地診療に活かすには」を掲載。

目次

  • 脂質異常症診療Q&A

    ―目次―

    第1章 脂質異常症治療の基本的な考え方（Q1〜9）
    第2章 脂質異常症の検査・診断（Q10〜30）
    第3章 脂質異常症の食事療法（Q31〜43）
    第4章 脂質異常症の運動療法（Q44〜60）
    第5章 脂質異常症の薬物療法（Q61〜79）
    第6章 原発性高脂血症の治療（Q80〜88）
    第7章 続発性高脂血症の治療（Q89〜95）
    第8章 メタボリックシンドロームに伴う脂質異常症の治療
    　　　　（Q96〜100）
    第9章 慢性腎疾患(CKD)疾患に伴う脂質異常症の治療（Q101〜104）
    第10章 脳卒中の脂質異常症の治療（Q105〜108）
    第11章 高齢者の脂質異常症の治療（Q109〜112）
    第12章 女性の脂質異常症の治療（Q113〜116）
    第13章 小児の脂質異常症の治療（Q117〜121）
    第14章 各種疾患に伴う脂質異常症の治療（Q122〜127）
    第15章 脂質異常症治療薬の概説（Q128〜139）
    第16章 脂質異常症キーワード解説

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第3章 脂質異常症の食事療法

P.40 掲載の参考文献
1) 多田紀夫 : 動脈硬化Q & A「検診の結果, 紹介来院した会社員」, J Atherosclr Thromb NEWS & ASCOPE 16 (4) supple (通巻45号) : 9-12, 2009
 
2) Keys A, Aravanis C, Blackburn H et al : Epidemiological studies related to coronary heart disease : characteristics of men aged 40-59 in seven countries. Acta Med Scand Suppl 460 : 1-392, 1967
 
3) Keys A, Parlin RW : Serum cholesterol response to changes in dietary lipids. Am J Clin Nutr 19 : 175-81, 1966
 
4) Denke MA : Dietary fats, fatty acids, and their effects on lipoproteins. Curr Atheroscler Reports 8 : 466-471, 2006
 
5) Hu FB, Willet WC : Optimal diets for prevention of coronary heart disease. JAMA 288 (20) : 2569-2578, 2002
 
6) 多田紀夫 : 多価不飽和脂肪酸と疾患 4) 脂質異常症. 治療学43 (8), 850-6, 2009
 
7) Pereira MA, Pins JJ : Dietary fiber and cardiovascular disease : experimental and epidemiologic advances. Curr Atheroscler Report 2 : 494-502, 2000
PubMed
P.42 掲載の参考文献
1) 多田紀夫 : 高脂血症治療の新たなステラテジー. 高脂血症の病態と診断. 「高脂血症の発生機序」, 治療82 (5) : 1487-1493, 2000
 
2) 多田紀夫 : メタボリックシンドロームの治療 : 食事療法 Prog Med 24 (9) : 2242-2248, 2004
Medical*Online
3) Hu FB, Willet W : Optimal diets for prevention of coronary heart disease. JAMA 288 : 2569-2578, 2002
 
4) Mozaffarian D : Effects of dietary fats versus carbohydrates on coronary heart disease : a review of the evidence. Curr Atheroscler Reports 7 1435-445, 2005
 
5) Malik VS and Hu FB Popular weight-loss diets : from evidence to practice. Nat Clin Pract Cardiovasc Med 4 : 34-41, 2007
 
6) Kris-Etherton PM, Harris WS, Appel LJ : American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106 : 2747-2757, 2003
 
7) Jacobson TA : Secondary prevention of coronary artery disease with omega-3 fatty acids. Am J Cardiol 98 : 61i-70i, 2006
PubMed
8) Riediger ND, Othman RA, Suh M et al : A systemic review of the roles of n-3 fatty acids in health and disease. J Am Diet Assoc 109 : 668-679, 2009
 
9) Mensink RP, Katan MB : Effect of dietary fatty acids on serum lipids and lipoproteins. A metaanalysis of 27 trials. Arterioscler Thromb 12 (8) : 911-919, 1992
PubMed
10) Bantle JP, Raatz SK, Thomas W et al : Effects of dietary fructose on plasma lipids in healthy sublects. Am J Clin Nutr 72 : 1128-34, 2000
 
11) Teff KL, Elliot SS, Tschoep M et al : Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increase triglycerides in women. J Clin Endocrin Metab 89 (6) : 2963- 72, 2004
 
12) Chandalia M, Garg A, Lutjohann D et al : Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 342 : 1392-8, 2000
PubMed
13) Schulze MB, Liu S, Rimm EB et al : Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr 80 : 348-56, 2004
PubMed
P.44 掲載の参考文献
1) 多出紀夫 : HDLの臨床的意義-介入試験の成績から. Therapeutic Res 23 (6) : 1135-1142, 2002
 
2) 多田紀夫 : 低HDL-コレステロール血症. 臨床と研究78 (5) : 830-836, 2001
 
3) 日本動脈硬化学会編 : 動脈硬化性疾患予防ガイドライン2007年版, 日本動脈硬化学会, 東京, 2007
 
4) Robins SJ, Collins D, Wittes JT et al : VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial : Relation of gemfibrozil treatment and lipid levels with major coronary events : VA-HIT : arandomized controlled trial. JAMA 285 (12) : 1585-1591, 2001
 
5) Tall AR : CETP inhibitors to increase HDL cholesterol levels. New Engl J Med 356 : 1364-1366, 2007
PubMed
P.45 掲載の参考文献
1) 日本動脈硬化学会編 : 動脈硬化性疾患予防ガイドライン2007年版, 日本動脈硬化学会, 東京, 2007
 
2) Lichtenstein AH, Appel LJ, Brands M et al : Diet and lifestyle recommendations revision 2006. a scientific statement from the American Heart Association Nutrition Committee. Circulation 114 : 82-96, 2006
PubMed
3) Hu FB, Willet W : Optimal diets for prevention of coronary heart disease. JAMA 288 : 2569-2578, 2002
 
P.48 掲載の参考文献
1) Malik VS and Hu FB : Popular weight-loss diets : from evidence to practice. Nat Clin Pract Cardiovasc Med 4 : 34-41, 2007
 
2) Dansinger ML Gleason JA, Griffith JL et al : Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction : arandomized trial. JAMA 293 (1) : 43-53, 2005
 
3) Gardner CD, Kiazand A, Alhassan S et al : Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women : the A TO Z Weight Loss Study : a randomized trial. JAMA 297 (9) : 969-977, 2007
 
4) Jeppesen J, Schaaf P, Jones C et al : Effects of low-fat, high-carbohydrate diets on risk factors for ischemic heart disease in postmenopausal women. Am J Clin Nutr 65 (4) : 1027-1033, 1997
PubMed
5) Poppitt SD, Keogh GF, Prentice AM et al : Long-term effects of ad libitum low-fat, high-carbohydrate diets on body weight and serum lipids in overweight subjects with metabolic syndrome. Am J Clin Nutr 75 (1) : 11-20, 2002
PubMed
6) Foster GD Wyatt HR, Hill JO et al : Arandomized trial of a low-carbohydrate diet for obesity. N Engl J Med 348 (21) : 2082-2090, 2003
 
P.49 掲載の参考文献
1) 多田紀夫 : 食後高脂血症 血管医学 3 (6) : 693-700, 2002
Medical*Online
2) Tada N, Watanabe H, Matsuo N et al : Dynamics of postprandial remnant-like lipoprotein particles in serum after loading of diacylglycerols. Clin Chim Acta 311 (2) : 109-117, 2001
PubMed
3) Tada N, Shoji K, Takeshita M et al : Effects of diacylglycerol ingestion on postprandial hyperlipidemia in diabetes. Clin Chim Acta 353 (1-2) : 87-94, 2005
PubMed
4) Tada N, Yoshida H : Diacylglycerol on lipid metabolism. Curr Opin Lipidol 14 (1) : 29-33, 2003
PubMed
5) Parks EJ, Krauss RM, Christiansen MP et al : Effects of a low-fat, high carbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J Clin Invest 104 (8) : 1087-1096, 1999
PubMed
6) Hu FB, Willett WC : Optimal diets for prevention of coronary heart disease. JAMA 288 (20) : 2569-2578, 2002
PubMed
7) Harbis A, Defoort C, Narbonne H et al : Acute hyperinsulinism modulates plasma apolipoprotein B-48 triglyceride-rich lipoproteins in healthy subjects during the postprandial period. Diabetes 50 (2) : 462-469, 2001
PubMed
8) Ceriello A, Quagliaro L, Piconi L et al : Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53 (3) : 701-710, 2004
PubMed
P.51 掲載の参考文献
1) 日本動脈硬化学会編 : 動脈硬化疾患予防ガイドライン2007年版
 
2) 医歯薬出版 : 臨床栄養 111 (No.1) : 135, 2007
 
3) 医歯薬出版 : 臨床栄養 110 (No.5) : 605, 2007
 
4) 医歯薬出版 : 臨床栄養 111 (No.3) : 399, 2007
 
P.52 掲載の参考文献
1) 日本動脈硬化学会編 : 動脈硬化疾患予防ガイドライン2007年版
 
2) 医歯薬出版 : 臨床栄養 113 (No.4) : 521-525, 2008
 
3) 多田紀夫 : その他の非薬物療法 (サプリメントの評価). 日本臨床65 (増刊号7) : 451-457, 2007
 
4) 厚生労働省 : 平成20年 国民健康栄養調査報告
 
P.53 掲載の参考文献
1) 医歯薬出版 : 臨床栄養 113 (No.4) : 521-525, 2008
 
2) 日本臨床 : 65 増刊号7 : 451-457, 2007
Medical*Online
3) 日本動脈硬化学会編 : 動脈硬化疾患予防ガイドライン2007年版
 
P.54 掲載の参考文献
1) 文部科学省 : 五訂増補日本食品標準成分表2005
 
2) 東京慈恵会医科大学附属柏病院栄養部 : 栄養出納表 2009
 
3) 日本動脈硬化学会編 : 動脈硬化疾患予防ガイドライン2007年版
 
4) 薬事日報社 : 機能性食品素材便覧臨床栄養2004年版, 139頁
 
P.55 掲載の参考文献
1) Knomhout D, Menotti A, Bloemberg B et al : Dietary saturated and trans fatty acids and cholesterol and 25-year mortality from coronary heart disease : the Seven Countries Study. Prev Med 24 : 308-315, 1995
 
2) Hu FB, Willet WC : Optimal diets for prevention of coronary heart disease. JAMA 288 (20) : 2569-2578, 2002
 
3) Denke MA : The effects of trans fatty acid ingestion on serum lipid concentration. Am J Clin Nutr 62 : 693s-700s, 1995
 
4) Ascherio A, Katan MB, Zock PL et al : Trans fatty acid and coronary heart disease. N Engl J Med 340 : 1994-1998, 1999
PubMed
5) Lichtenstein AH : Trans fatty acids, plasma lipid levels, and risk of developing cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 95 : 2588-2590, 1997
PubMed
P.57 掲載の参考文献
1) Jenkins DJ, Wolever TM, Taylor RH et al : Glycemic index of foods : aphysiological basis for carbohydrate exchange. Am J Clin Nutr 34 (3) : 362-366. 1981
 
2) Thomas D, Elliott E : Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database Syst Rev Issue 1. Art. No. : CDOO6296, 2009
 
3) Brand-Miller J, Petocz P, Hayne S et al : Low-glycemic index diets in the management of diabetes. Diabetes Care 26 : 2261-2267, 2003
PubMed
4) Schulze MB, Liu S, Rimm EB et al : Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr 80 : 348-356, 2004
PubMed
5) Hu FB, WiUet W : Optimal diets for prevention of coronary heart disease. JAMA 288 : 2569-2578, 2002
 
6) Bantle Jp, Raatz SK, Thomas W et al : Effects of dietary fructose on plasma lipids in healthy subjects. Am J Clin Nutr 72 : 1128-1134, 2000
PubMed
7) Teff KL, Elliot SS, Tschoep M et al : Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increase triglycerides in women. J Clin Endocrin Metab 89 (6) : 2963-2972, 2004
 
P.59 掲載の参考文献
1) Keys A, Aravanis C, Blackburn H et al : Epidemiological studies related to coronary heart disease : characteristics of men aged 40-59 in seven countries. Acta Med Scand Suppl 460 : 1-392, 1967
 
2) Tunstall-Pedoe H, Kuulasmaa K, Mahonen M et al, : Contribution of trends in survival and coronary event rate to changes in coronary heart disease mortality : 10-year results from 37 WHO MONICA Project populations. Lancet 353 : 1547-1555, 1999
PubMed
3) Tunstall-Pedoe H, Kuulasmaa K, Amouyel P et al : Myocardial infarction and coronary deaths in the World Health Organization MONICA Project : Registration procedures, event rates, and case fatality rates in 38 populations from 21 countries in four continents. Circulation 90 : 583-561, 1994
PubMed
4) 日本循環器管理協議会 : 「1980年循環器疾患基礎調査」追跡調査報告書, 35～81, 1995
 
5) Stamler J, Wentworth D, Neaton JD : Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256 : 2823-2828, 1986
PubMed
6) Marmot MG, Syme SL, Kagan A et al : Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California : prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol 102 : 514-525, 1975
PubMed
7) 太田保世 : 理想の食事-武玉川に見る元禄の食事とマクガバン・レポート-. 東海大学出版会, 神奈川, 2009
 
8) Sekikawa A, Curb JD, Ueshima H et al ; ERA JUMP (Electron-Beam Tomography, Risk Factor Assessment Among Japanese and U. S. Men in the Post-World War II Birth Cohort) Study Group : Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men : a cross-sectional study. J Am Coll Cardiol 52 (6) : 417-24, 2008
 
9) Kitamura A, Sato S, Kiyama M et al : Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003 : the Akita-Osaka study. J Am Coll Cardiol 52 (1) : 71-79, 2008
PubMed

第4章 脂質異常症の運動療法

P.61 掲載の参考文献
1) Morris JN et al : Coronary heart disease and physical activity of work. Lancet2 : 1207～1210, 1953
 
2) Paffenbarger RS Jr et al : Physical activity, all-cause mortality, and longevity of college alum-mi. N Engl J Med 314 : 605～613, 1986
 
3) Blair SN et al : Physical fitness and all-cause mortality-a prospective study on healthy men and women-. JAMA 262 : 2395～2401, 1989
 
P.63 掲載の参考文献
1) Despres JP, Lamarche B : Low-intensity and endurance exercise training, Plasma lipoproteins, and the risk of coronary heart disease. J Intern Med 236 : 7-22, 1994
PubMed
2) Durstine JL, Grandjean PW, Cox CA, Thompson PD : Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil 22 : 385-398, 2002
PubMed
P.73 掲載の参考文献
1) Tashiro E, Miura S, Koga M, Sasaguri M, Ideishi M, et al : Crossover comparison between the depressor effects of low and high work-rate exercise in mild hypertension. Clin Exp Pharmacol Physiolo 20 : 689-696, 1993
 
P.75 掲載の参考文献
1) 我が国の心疾患患者の学校, 職域, スポーツにおける運動許容条件に関するガイドライン2008年改訂版
 
2) 上嶋健治 : 先進医療としての心臓. 日内会誌 96 : 2546-2553, 2007
 
P.76 掲載の参考文献
1) 野村秀樹, 井口昭久 : 運動療法 新老年学 折茂肇編集, p399-404, 東京大学出版, 東京, 2000年6月
 
P.77 掲載の参考文献
1) American College of Sports Medicine : Guideline for Exercise Testing and Prescription, 4th Ed, Lea & Febiger, Philadelphia, 1991 ; 日本体力医学会体力科学編集委員会 : 運動処方の指針, 南江堂, 東京, 1993
 
P.78 掲載の参考文献
1) Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, et al : Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. A statement from the council on clinical cardiology (subcommittee on exercise, rehabilitation, and prevention) and the council on nutrition, physical activity, and metabolism (subcommittee on physical activity). Circulation 107 : 3109-3116, 2003
PubMed
2) Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, et al : Exercise standards for testing and training. A statement for healthcare professionals from the American Heart Association. Circulation 104 : 1694-1740, 2001
PubMed

第7章 続発性高脂血症の治療

P.101 掲載の参考文献
1) Lally S et al : Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes : the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 49 : 1008-1016, 2006
PubMed
2) Gylling H et al : Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease, Atherosclerosis 126 : 325-332, 1996
PubMed
3) Lally S et al : Genes that affect cholesterol synthesis, cholesterol absorption, and chylomicron assembly : the relationship between the liver and intestine in control and streptozotosin diabetic rats. Metabolism 56 : 430-438, 2007
PubMed
4) Hori M et al : Acyl-coenzyme A : cholesterol acyltransferase-2 (ACAT-2) is responsible for elevated intestinal ACAT activity in diabetic rats. Diabetes 31 : 283-291, 1982
 
5) Phillips C, et al : Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects : the relationship to triglyceride-rich postprandial lipoprotein composition. Atherosclerosis 187 : 57-64, 2006
PubMed
6) Jiao S et al : Influence of endogenous hyperinsulinism on high density lipoprotein 2 level in type 2 diabetes mellitus and impaired glucose tolerance. Atherosclerosis 60 : 279-286, 1986
PubMed
P.102 掲載の参考文献
1) Baigent C et al ; Cholesterol Treatment Trialists' (CTT) Collaborators : Efficacy and safety of cholesterol-lowering treatment : prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 366 : 1267-1278, 2005
PubMed
2) Rajpathak SN et al : Statin therapy and risk of developing type 2 diabetes : ameta-analysis. Diabetes Care 32 : 1924-1929, 2009
 
3) Vijan S et al : Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus : background paper for the American College of Physicians. Ann Intem Med 140 : 650-658, 2004
 
P.105 掲載の参考文献
1) Fioretto P et al : Residual microvascular risk in diabetes : unmet needs and future directions. Nat Rev Endocrinol 6 : 19-25, 2010
 
2) Kameda K et al : Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. Atherosclerosis 51 : 241-249, 1984
PubMed
3) Turner RC et al : Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus : United Kingdom Prospective Diabetes Study (UKPDS : 23). BMJ 316 : 823-828, 1998
PubMed
4) Sone H et al : Japan Diabetes Complication Study Group : Obesity and type 2 diabetes in Japanese patients. Lancet 361 : 85, 2003
 
5) Lyons T et al : Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 45 : 910-918, 2004
PubMed
6) Keech AC et al : Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study) : arandomised controlled trial. Lancet 370 : 1687-1697, 2007
PubMed
7) Sandhu S et al : Statins for improving renal outcomes : ameta-analysis. J Am Soc Nephrol 17 : 2006-2016, 2006
 
8) Vidt DG : Statins and proteinuria. Curr Atheroscler Rep 7 : 351-357, 2005
PubMed
9) Law M et al : Statin safety : a systematic review. Am J Cardiol 97 (Suppl 1) : 52C-60C, 2006
 
10) Tesfaye S et al : Vascular risk factors and diabetic neuropathy. N Engl J Med 352 : 341-350, 2005
PubMed
P.106 掲載の参考文献
1) Walsh Jp et al : Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 165 : 2467-2472, 2005
PubMed
2) Ito M et al : Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients. J Clin Endocrinol Metab 92 : 608-611, 2007
PubMed
3) Chu JW et al : The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab 86 : 4591-4599, 2001
 
P.107 掲載の参考文献
1) Shurraw S et al : Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 26 : 523-539, 2006
PubMed
2) Ordonez JD et al : The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44 : 638-642, 1993
PubMed
3) Saito T et al : Lipoprotein glomerulopathy : glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis 13 : 148-153, 1989
 
4) Arai T et al : Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis 169 : 293-299, 2003
 
P.109 掲載の参考文献
1) Hiraoka H, Yamashita S, Matsuzawa Y, Kubo M, Nozaki S, Sakai N, Hirano K, Kawata S, Tarui S : Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis : relationship to abnormalities in high-density lipoprotein. Hepatology 18 : 103-110, 1993
PubMed
2) Sorokin A, Brown JL, Thompson PD : Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk : a systematic review. Atherosclerosis 194 : 293-299, 2007
 

第8章 メタボリックシンドロームに伴う脂質異常症の治療

P.115 掲載の参考文献
1) Packard CJ et al : Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 41 : 305-317, 2000
PubMed
2) Syvanne M et al : Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 350 : S120-123. 1997
 
3) Kathiresan S et al : Increased small low-density lipoprotein particle number : a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113 : 20-29, 2006
PubMed
4) Okazaki M et al : Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in highperformance liquid chromatography. Arterioscler Thromb Vasc Biol 25 : 578-584, 2005
PubMed

第10章 脳卒中の脂質異常症の治療

P.122 掲載の参考文献
1) Imanura T et al : Stroke 40 : 382-388, 2009
 
2) Amarenco P et al. Lancet Neurol 8 : 453-463, 2009
PubMed
P.123 掲載の参考文献
1) 半田伸夫 : 臨床検査48 : 1385-1396, 2004
 
1) Iso H et al : N Engl J Med 320 : 904-910, 1989
PubMed
2) Noda H et al : Circulation 119 : 2136-2145, 2009
PubMed
P.124 掲載の参考文献
1) Amarenco P et al : Stroke 35 : 2902-2909, 2004
PubMed
2) Goldstein LB et al : Neurology 70 : 2364-2370, 2008
PubMed

第11章 高齢者の脂質異常症の治療

P.132 掲載の参考文献
1) 動脈硬化性疾患予防ガイドライン2007年版 : 日本動脈硬化学会, 2007
Medical*Online
2) The Pooling Project Research Group : Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events : final report of the pooling Project. The pooling Project research group. J Chron Dis 31 : 201-306, 1978
 
3) Harris TB, Makuc DM, Kleinman JC et al : Is the serum cholesterol-coronary heart disease relationship modified by activity level in older persons? J Am Geriatr Soc. 39 : 747-754, 1991
 
4) Yokoyama M, Origasa H ; JELIS Investigators : Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia : rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J ; 146 : 613-620, 2003
PubMed

第12章 女性の脂質異常症の治療

P.136 掲載の参考文献
1) Kimura Y, Takishita S et al : Internal Medicine 37 : 736-745, 1998
PubMed
2) Research Committee on Serum Lipid Survey 1990 in Japan. J Atheroscler Thromb 2, 122-132, 1996
PubMed
3) Mizuno K, Nakaya N et al : Circulation 117, 494-502, 2008
PubMed

第14章 各種疾患に伴う脂質異常症の治療

P.144 掲載の参考文献
1) Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM ; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis : the ASTEROID triaL JAMA 295 : 1556-1565, 2006
 
P.146 掲載の参考文献
1) Kubo M et al : Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community : the Hisayama study. Stroke 34 : 2349-2354, 2003
 
2) Sever PS et al : Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) : a multicentre randomised controlled trial. Lancet 361 : 1149-1158, 2003
 
3) Kushiro T et al : Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension 53 : 135-141 2009
PubMed
4) Golomb BA et al : Reduction in blood pressure with statins : results from the UCSD Statin Study, a randomized trial. Arch Intern Med 168 : 721-727, 2008
PubMed
P.148 掲載の参考文献
1) Havel RJ : Pathogenesis, differentiation and management of hypertriglyceridemia. Adv Intern Med 15 : 117-154, 1969
PubMed
2) Lennertz A et al : Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apher 3 : 227-233, 1999
PubMed
P.149 掲載の参考文献
1) Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T ; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators : Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes : the MIRACL study : arandomized controlled trial : JAMA 285 : 1711-1718, 2001
 
2) Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM ; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 : 1495-504, 2004
PubMed
3) Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H : Early statin treatment in patients with acute coronary syndrome : demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event : the ESTABLISH Study. Circulation 110 : 1061-8, 2004
PubMed
4) Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A ; MUSASHI-AMI Investigators : Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction : subanalysis of MUSASHI-AMI. Circ J 71 : 1348-1353, 2007
PubMed
5) Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, Li Y, Yajima J, Nanto S, Takazawa K, Kodama K : Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy. Circ J 73 : 718-725, 2009
PubMed
6) Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M : JAPAN-ACS Investigators ; Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome : a multicenter randomized trial evaluated by volumetric intravascular ultrasound using Pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54 : 293-302, 2009
 
P.151 掲載の参考文献
1) 清家廣政ほか : 教職員における血清尿酸値を中心とした臨床的検討. 尿酸7 : 172-181, 1983
 
2) Vuorinen-Markkola H and Yki-Jarvinen H : Hyperuricemia and irlsulin resistance. J Clin Endocrinol Metab 78 : 25-29, 1994
PubMed
3) Moriwaki Y et al : Apolipoprotein E phenotypes in patients with gout : relatlon with hypertriglyceridaemia. Ann Rheum Dis 54 : 351-354, 1995
PubMed
4) Dessein PH et al : Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout : a pilot study. Ann Rheum Dis 59 : 539-543, 2000
 
5) Milionis HJ et al : Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 148 : 635-640, 2004
PubMed
P.152 掲載の参考文献
1) Hyogo H et al : Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 57 : 1711-1718, 2008
PubMed
2) Athyros VG et al : Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome : a randomised study. Curr Med Res Opin 22 : 873-883, 2006
PubMed
3) Aithal GP et al : Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135 : 1176-1184, 2008
PubMed

第15章 脂質異常症治療薬の概説

P.155 掲載の参考文献
1) Goldstein JL, DeBose-Boyd RA, and Brown MS : Cell 124 : 35-46, 2006
 
2) Sakai A, Kume N, Nishi E et al : P-selectin and vascular cell adhesion molecule-1 are focally expressed in aortas of hyperchlesterolemic rabbits before intimal accumulation of macrophages and T lymphocytes. Arterioscler Thromb Vasc Biol 17 : 310, 1997
 
P.157 掲載の参考文献
1) Nakamura H, Arakawa K, Itakura H et al : Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study) a prospective randomised controlled trial. Lancet 368 : 1155-1163, 2006
PubMed
P.160 掲載の参考文献
1) Lipid Research Clinic Program : The Lipid Research Clinic Coronary Primary Prevention Trial Results I. Reduction in incidence of coronary heart disease. JAMA 251 : 351-364, 1984
 
2) Lipid Research Clinic Program : The Lipid Research Clinic Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowing. JAMA 251 : 365-374, 1984
 
3) Watts GF et al : Effects on coronary artery diease of lipid-lowering diet, or diet plus chlestyramin, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339 : 563-569, 1992
 
P.163 掲載の参考文献
1) Tardif JC et al : Canadian Antioxidant Restenosis Trial (CART-1) Investigators : Effect of AGI-1067 and probucol after percutaneous coronary angioplasty. N Engl J Med 337 : 365-372, 1997
 
2) Long-Term Probucol Treatment Prevents Secondary Cardiovascular Events : a Cohort Study of Patients with Heterozygous Familial Hypercholesterolemia in Japan. J Atherosc Thromb 15 (No.6) : 292-302, 2008
PubMed
P.164 掲載の参考文献
1) Niacin-Based Therapy for Dyslipidemia : Past Evidence and Future Advances. Mattew K Ito, Pharm D : The American Journal of Managed Care. 8 (NO.12) Supl, 2002
 
2) 日本動脈硬化学会編 : 動脈硬化性疾患予防のための脂質異常症治療ガイド2008年版
 
3) McCormacl PL et al : Prolonged-release nicotic acid : areview of its use in the treatment of dyslipidemia. Drugs 65 (18) ; 2719-2740, 2005
 
4) Rosenson RS : Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 171 (1) : 87-96, 2003
PubMed
P.165 掲載の参考文献
1) The Coronary Drug Project Research Group : Clofibrate and niacin in coronary heart disease. JAMA 231 : 360-381, 1975
 
2) Carlson LA et al : Reduction of mortality in the Stockhoim Ischemic Heart Disease Secondary Prevention Study by combination treatment with clofibrate and nicotinic acid. Acta Med Scand 223 : 40-418, 1988
 
3) Grundy SM et al : Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type2 diabetes : results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intrn Med 162 : 1568-1567, 2002
 
4) Brown BG et al : Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 : 1583-1592, 2001
 
P.166 掲載の参考文献
1) Dyerberg J, Bang HO, Stoffersen E et al : Eicosapentaenoic acid and prevention of thrombosis and athrosclerosis? Lancet2 (8081) : 117-119, 1978
 
2) Calder PC : n-3 polyunsaturated fatty acid, inflammation, and inflammatory diseases. Am J Clin Nutr 83 (6 Suppl) : 1505S-19S, 2006
 
P.168 掲載の参考文献
1) Yokoyama M, Origasa H, Matsuxaki M et al. : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolemic patients (JELIS) : a randomized open-label, blinded endpoint analysis. Lancet 369 (9567) : 1090-1098, 2007
 

書評

最近チェックした商品履歴

Loading...